Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40

Benzinga · 1d ago
Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $36 to $40.